Tag: Imprime PGG

Biothera Pharmaceuticals Commences Phase 2 Head and Neck Cancer Study Evaluating Combination of Imprime PGG and Merck’s KEYTRUDA® (pembrolizumab)

Study Is Second Clinical Research Collaboration with Merck EAGAN, MN — February 6, 2018 — Biothera Pharmaceuticals, Inc. announced today that patient treatment has commenced in its Phase 2 clinical study in squamous cell carcinoma of the head and neck (SCCHN).  The research collaboration with Merck (known as MSD outside the United States and Canada) will evaluate Biothera’s Imprime PGG in combination with KEYTRUDA® (pembrolizumab),...

Read More


Biothera Pharmaceuticals Presents Preclinical Data Showing Imprime PGG Activates Natural Killer Cell-Mediated Tumor Killing

Data Presented at AACR-NCI-EORTC International Conference EAGAN, MN — October 30, 2017 — Biothera Pharmaceuticals, Inc. announced today the presentation of new preclinical findings showing that the Company’s Phase 2 cancer immunotherapy Imprime PGG activates Natural Killer (NK) cell-mediated killing of cancer cells. The data were presented at the ongoing AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics: Discovery, Biology, and Clinical Applications, taking...

Read More


Biothera Pharmaceuticals Announces Initiation of Phase 1b/2 Clinical Study Evaluating Combination of Imprime PGG and Merck’s KEYTRUDA in Non-Small Cell Lung Cancer

Big Ten Cancer Research Consortium conducting trial with funding from Merck EAGAN, MN — July 19, 2017 — Biothera Pharmaceuticals, Inc. today announced that the Big Ten Cancer Research Consortium has begun patient dosing in a Phase 1b/2 clinical study to evaluate Biothera’s Imprime PGG in combination with the Merck anti-PD-1 therapy, KEYTRUDA® (pembrolizumab) in second-line non-small cell lung cancer (NSCLC).  The University of Illinois...

Read More


Biothera Pharmaceuticals’ Phase 2 Study of Imprime PGG Combination Therapy in Non-Small Cell Lung Cancer Patients Published in Investigational New Drugs

EAGAN, MN — March 24, 2017 — Biothera Pharmaceuticals, Inc. today announced peer-reviewed publication of results of a randomized Phase 2 clinical study of the Company’s cancer immunotherapy Imprime PGG in combination with Erbitux® (cetuximab) and chemotherapy in metastatic non-small cell lung cancer (NSCLC) patients. The study findings have been published online in the journal Investigational New Drugs. Completed by Biothera in 2013, the study was...

Read More


Biothera Pharmaceuticals to Discuss Imprime PGG Combination Therapy with Checkpoint Inhibitors at Molecular Medicine Tri-Conference 2017

EAGAN, MN — February 15, 2017 — Biothera Pharmaceuticals, Inc. today announced that it will deliver two presentations on its Phase 2 candidate Imprime PGG at the 24th annual Molecular Medicine Tri-Conference, taking place at the Moscone North Convention Center, San Francisco, February 19-24, 2017. Jeremy R. Graff, Ph.D., Chief Scientific Officer and Senior Vice President, Research at Biothera Pharmaceuticals, will present data showing that...

Read More


Biothera Pharmaceuticals and Merck Further Expand Research Collaboration to Include Phase 2 Clinical Trial in Head and Neck Cancer

Trial to Test Combination of Biothera’s Imprime PGG and Merck’s KEYTRUDA® (pembrolizumab) EAGAN, MN — December 5, 2016 — Biothera Pharmaceuticals, Inc. today announced an expansion of its research collaboration with Merck (known as MSD outside the United States and Canada) to include a Phase 2 clinical study investigating Biothera’s Imprime PGG in combination with KEYTRUDA® (pembrolizumab), Merck’s anti-PD-1 therapy, in second- and third-line patients...

Read More


Biothera Pharmaceuticals Announces Data Demonstrating Unique Immune Response Profile Generated by Phase 2 Cancer Immunotherapy Imprime PGG

Researchers to Present Preclinical Data at EORTC-NCI-AACR Symposium EAGAN, MN — November 29, 2016 — Biothera Pharmaceuticals, Inc. will present data tomorrow illustrating the unique cytokine response generated by its phase 2 cancer immunotherapy Imprime PGG, the only Pathogen Associated Molecular Patterning (PAMP) molecule that has been successfully administered systemically. The data will be highlighted in two poster presentations at the 28th EORTC-NCI-AACR Symposium on Molecular...

Read More


Preclinical Data Published in PLOS ONE Support Use of a Patient Selection Biomarker for Biothera Pharmaceuticals’ Phase 2 Cancer Immunotherapy Imprime PGG

Formation of Imprime PGG-Immune Complex Essential to Anti-Tumor Activity EAGAN, MN — November 7, 2016 — Biothera Pharmaceuticals, Inc. today announced the publication of preclinical research identifying an essential mechanism in the activation of anti-cancer immune responses by Imprime PGG, the Company’s Phase 2 cancer immunotherapy drug. The formation of an immune complex between Imprime PGG and endogenous anti-beta glucan antibodies (ABA) offers the potential...

Read More


MIT Research: Targeting Both Innate and Adaptive Immunity may be the Key to Enhancing the Effectiveness of Cancer immunotherapy

Last week scientists at the Massachusetts Institute of Technology provided compelling new preclinical research that large, aggressive tumors in mice could be eradicated by combining a series of immune therapies to activate both the innate and adaptive immune systems. Immunologic rejection of these large, advanced tumors was achieved through an orchestrated immune attack triggered by the rational combination of immune-modulatory agents, each of which was...

Read More


Clinical Data Support Mechanism of Action and Patient Selection Biomarker for Imprime PGG, Biothera Pharmaceutical’s Phase 2 Cancer Immunotherapy

Clinical findings presented at CRI-CIMT-EATI-AACR International Cancer Immunotherapy Conference EAGAN, MN — September 27, 2016 — Biothera Pharmaceuticals, Inc. today announced the presentation of clinical data demonstrating the mechanism of action of Imprime PGG, the Company’s Phase 2 cancer immunotherapy drug, in healthy human volunteers. These are the first data to show that when administered intravenously to healthy human subjects, Imprime PGG drives the immunopharmacodynamic...

Read More



Page 1 of 41234